🔎 Trials Near Me

Home › Leg Injuries and Disorders › NCT06050668

Essential Amino Acid Supplementation for Femoral Fragility Fractures

RecruitingPhase 2

MEND Repair & Recover Clinical Trial

Who can join

Ages 65 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Hospital inpatient
* Age ≥ 65 years old on admission
* Low-energy mechanism of injury
* Diagnosis of femur fracture (OTA 31, 32, or 33 fracture)
* Indicated for surgical fixation
* Able to provide informed consent

Exclusion Criteria:

* Part of a vulnerable population (ex: Incarcerated, Non-English speaking)
* Cognitive impairment (MMSE score ≤ 17)
* Electrical medical implant (ex: Pacemaker/Defibrillator, Left Ventricular Assist Device, Cochlear implant, Insulin pump, Pain medication pumps, Spinal cord stimulator)
* Non-ambulatory prior to injury
* Inability to consume an oral diet or allergy to supplement ingredients (ex: milk allergy)
* Concern for inability to complete follow-up
* Hemi or total arthroplasty (joint replacement)
* Patients with a historical diagnosis of chronic kidney disease (CKD)

About the study

This trial will evaluate the impact of 4 weeks of postoperative essential amino acid (EAA)-based supplementation on muscle morphology after femoral fragility fracture. This trial will assess the ability of EAA-based to increase skeletal muscle metabolic activity, reduce inflammation, and induce muscle fiber hypertrophy, as well as preserve skeletal muscle mass and physical performance up to 6 months after injury. Participants will be randomized in a 1:1 ratio to 1) standard of care (no dietary intervention) or 2) EAA-based supplementation.

What is being tested

Sponsor: Michael C Willey · Participants: 60 · Started: Jun 17, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT06050668

Locations in the U.S.

IowaUniversity of Iowa Health Care, Iowa City
OregonSlocum Center for Orthopedics & Sports Medicine, Eugene (Not yet recruiting)

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.